SCHEMBL2178379

SCHEMBL2178379

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.52
DGAT1 O75907 6/20 0.50
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
MAPT P10636 2/20 0.48
HTT P42858 2/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CSGALNACT1 Q8TDX6 1/20 0.47
THRB P10828 1/20 0.47
NTRK1 P04629 3/20 0.44
NTRK2 Q16620 3/20 0.44
AURKB Q96GD4 3/20 0.44
CSF1R P07333 2/20 0.44
KIT P10721 2/20 0.44
FLT1 P17948 2/20 0.44
EPHA2 P29317 2/20 0.44
FLT4 P35916 2/20 0.44
FLT3 P36888 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179431 1.00 KDR (0.52) KDRDGAT1KMT2AMEN1MAPT
SCHEMBL2178373 1.00 KDR (0.52) KDRDGAT1KMT2AMEN1MAPT
SCHEMBL2179086 0.93 THRB (0.46) KDRDGAT1MAPTHTTSMN1; SMN2
SCHEMBL2178767 0.93 THRB (0.46) KDRDGAT1MAPTHTTSMN1; SMN2
SCHEMBL2178546 0.93 DGAT1 (0.54) KDRDGAT1KMT2AMEN1MAPT
SCHEMBL2182706 0.93 DGAT1 (0.54) KDRDGAT1KMT2AMEN1MAPT
SCHEMBL2178541 0.93 DGAT1 (0.54) KDRDGAT1KMT2AMEN1MAPT
SCHEMBL2179995 0.92 DGAT1 (0.45) KDRDGAT1CSGALNACT1THRBTP53
SCHEMBL2179990 0.92 DGAT1 (0.45) KDRDGAT1CSGALNACT1THRBTP53
SCHEMBL2178369 0.92 DGAT1 (0.50) KDRDGAT1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT KDR 4082/4885DGAT1 1/4885KMT2A 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.